Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. A feasibility pilot study
Emiliano Calvo (1), Javier Cortés (1), María González-Cao (1), Javier Rodríguez (1), José Manuel Aramendía (1), Óscar Fernández-Hidalgo (1), Salvador Martín-Algarra (1), José Esteban Salgado (1), Rafael Martínez-Monge (2), Jokin de Irala (3), Antonio Brugarolas (1).
Department of Oncology, Divisions of (1) Medical Oncology and (2) Radiotherapy, Clínica Universitaria de Navarra, University of Navarra, and (3) Department of Epidemiology and Public Health, School of Medicine, University of Navarra, Navarra, Spain
Fecha: 01-oct-2002Oncología Radioterápica Área de Tumores de Tubo Digestivo Oncología Médica
To evaluate the feasibility and a possible activity range of combination irinotecan (CPT-11), oxaliplatin, and 5-FU in advanced colorectal cancer (ACC).
PATIENTS AND METHODS
A total of 53 patients (51% chemoresistant) were treated. Twenty-eight received monthly intravenous oxaliplatin (120 mg/m2) and CPT-11 (250 mg/m2) on day 1 and a course of 5-FU; these constituted the IRI250 group. Twenty-five received monthly intravenous oxaliplatin (120 mg/m2), CPT-11 (300 mg/m2) on day 1, and a course of 5-FU (IRI300 group). 5-FU administration was carried out as follows. Those with predominant hepatic disease (n = 32) received an intra-arterial infusion of 5-FU (2,500 mg/day on days 1-4); these were the IA-FU group. The remaining 21 patients received intravenous 5-FU (2,600 mg/m2 plus leucovorin 500 mg/m2 on days 1 and 15); these constituted the IV-FUFOL group.
Intention-to-treat response rate was 54.7% (4 CR, 7.5%). Twelve patients (22.5%) had stable disease; only 4 (7.5%) progressed. Median progression-free and overall survivals were 10 and 18 months, respectively. One-year progression-free and overall survival rates were 44.3 and 67.4%, respectively. Grade 3-4 toxicities included diarrhea (45.3% of patients), neutropenia (52.8%), mucositis (13.2%), and emesis (11.3%). There were 3 treatment-related deaths (5.7%), all in the IA-FU/IRI300 subgroup. Severe adverse effects requiring chemotherapy dose adjustment were observed in 67.9% of the patients, with odds ratios 9.04-fold higher in the IA-FU/IRI300 group (95% CI: 1.07-76.20) and 0.23-fold lower in the IV-FUFOL/IRI250 group (95% CI: 0.05-0.97).
This combination seems to have substantial activity in ACC. Overall toxicity was unacceptable in the IA-FU and IRI300 groups, with diarrhea and cytopenia constituting the dose-limiting side effects. Tolerance and efficacy profiles achieved with IV oxaliplatin (120 mg/m2 day 1), IV CPT-11 (250 mg/m2 day 1) and IV 5-FU 2.6 g/m2 with IV leucovorin (500 mg/m2 days 1 and 15) was favorable and deserves further investigation.
CITA DEL ARTÍCULO Oncology. 2002;63(3):254-65
tal vezLE INTERESE
La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.
Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.
Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.